Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET

Company Participants

Monique Kosse - LifeSci Advisors

James Caruso - CEO

Chad Kolean - CFO

Shane Lea - CCO

Andrei Shustov - SVP, Medical

Conference Call Participants

Jonathan Aschoff - ROTH MKM

Jeffrey Jones - Oppenheimer

Ahu Demir - Ladenburg

Jason McCarthy - Maxim Group

Operator

Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead.

Monique Kosse

Thank you, operator, and welcome, everyone. This morning, Cellectar issued a press release providing a corporate update. You may access that release on the company's website under the Investors tab. With us today are Jim Caruso, President and CEO of Cellectar; Chad Kolean, Chief Financial Officer; Jarrod Longcor, Chief Operating Officer; Shane Lea, Chief Commercial Officer; and Andrei Shustov, VP Medical. Following our prepared remarks, we will open the call for a Q&A session.

Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to Cellectar's expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties that could differ materially from those forecast due to the impact of many factors beyond the control of Cellectar. The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise.

Participants are directed to the cautionary notes set forth in today's press release as well as the risk factors set forth in Cellectar's annual report filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements.

Now I would like to turn the call over to Jim Caruso, President and Chief Executive Officer of Cellectar. Jim?

James Caruso

Thank you, Monique, and good morning, everyone. It is my pleasure to welcome you to our conference call highlighted by this morning's announcement that top line data from our CLOVER-WaM pivotal study in Waldenstrom macroglobulinemia is planned to be announced the week of January 8, 2024 during the JP Morgan Healthcare Conference. We continue to collect and evaluate patient data from our pivotal trial and view this announcement as a potentially transformational event for the company. And as such, merits increased awareness and an attentive audience, which the JP Morgan Healthcare Conference will certainly provide.